

Variant: NM_000104.4(CYP1B1):c.431A>G (p.Gln144Arg)

Version: 1.0

CA1620036 [↗](#)

1329081 (ClinVar) [↗](#)

Gene: CYP1B1 (HGNC:1545)

Condition: CYP1B1-related glaucoma with or without anterior segment dysgenesis (MONDO:0800472)

Inheritance Mode: Autosomal recessive inheritance

UUID: f5eaacff-9204-432f-905a-41b83607f51d

Approved on: 2025-11-19

Published on: 2025-11-18

HGVS expressions

NM_000104.4:c.431A>G

NM_000104.4(CYP1B1):c.431A>G (p.Gln144Arg)

NC_000002.12:g.38074958T>C

CM000664.2:g.38074958T>C

NC_000002.11:g.38302101T>C

CM000664.1:g.38302101T>C

NC_000002.10:g.38155605T>C

NG_008386.2:g.6144A>G

ENST00000490576.2:c.431A>G

ENST00000610745.5:c.431A>G

ENST00000494864.1:c.-70-3648A>G

ENST00000610745.4:c.431A>G

ENST00000613082.1:n.376-550A>G

ENST00000614273.1:c.431A>G

NM_000104.3:c.431A>G

Uncertain Significance

Met criteria codes **1**

PM2_Supporting

Not Met criteria codes **15**

BA1 PP1 PP3 PM1 PM3
PM5 PM4 PVS1 BS1 BS4
BP4 BP7 PS1 PS2 PS3

Evidence Links **1**

Expert Panel

Glaucoma VCEP [↗](#)

Criteria Specification Information

[↗](#) **Criteria Specification:** ClinGen Glaucoma Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for CYP1B1 Version 1.0.0

[↗](#) **Criteria Specification Approval History**

[↗](#) **Criteria Specifications for this VCEP**



Evidence submitted by expert panel

Glaucoma VCEP



The c.431A>G variant in CYP1B1 is a missense variant predicted to cause substitution of Glutamine by Arginine at amino acid 144 (p.Gln144Arg). The highest minor allele frequency of this variant was in the South Asian genetic ancestry group of gnomAD (v4.1) = 0.0003193 (28 alleles out of 87702), which met the ≤ 0.0005 threshold set for PM2_Supporting in a genetic ancestry group of at least



2,000 alleles. This missense variant was not predicted to affect splicing, as assessed with SpliceAI (≤ 0.1), and the REVEL score = 0.445, which was neither above nor below the thresholds for PP3 (≥ 0.644) or BP4 (≤ 0.290), predicting a damaging or benign impact on CYP1B1 function. PS3_Supporting was not applied as the assays reported did not meet the OddsPath threshold (> 2.1) or the threshold for abnormal impact on protein function in the assay could not be determined (PMID: 27243976). This variant has not been identified as homozygous or compound heterozygous with one other variant. One affected individual carries the Gln144Arg variant but they also carry two other CYP1B1 variants (Phe156Cys and His413_I414delinsGlnLys, both VUS), phase unknown. This person is excluded from assessing PM3 as the causative variant cannot be determined. In summary, this variant met the criteria to receive a score of 1 and to be classified as a variant of uncertain significance (uncertain significance classification range -1 to 5, adapted from PMID: 32720330) for CYP1B1-related glaucoma with or without anterior segment dysgenesis (ASD) based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v1.0, 06.11.2025): PM2_Supporting.



Met criteria codes



PM2_Supporting   The highest minor allele frequency of this variant was in the South Asian genetic ancestry group of gnomAD (v4.1) = 0.0003193 (28 alleles out of 87702), which met the ≤ 0.0005 threshold set for PM2_Supporting in a genetic ancestry group of at least 2,000 alleles.



Not Met criteria codes



BA1   This criterion was not met as PM2_Supporting has been met.



PP1   No segregations have been reported for this variant.



PP3   This missense variant was not predicted to affect splicing, as assessed with SpliceAI (≤ 0.1), and it had a REVEL score = 0.445, which did not meet the ≥ 0.644 threshold required for PP3.



PM1   This missense variant is located outside well-established functional domains.



PM3   This variant has not been identified as homozygous or compound heterozygous with one other variant. One affected individual carries the Gln144Arg variant but they also carry two other CYP1B1 variants (Phe156Cys and His413_I414delinsGlnLys, both VUS), phase unknown. This person is excluded from assessing PM3 as the causative variant cannot be determined.



PM5   PM5 did not apply to this variant at any strength as it did not meet PP3.

PM4   This criterion did not apply to this variant.










PVS1   This criterion did not apply to this variant.

BS1   This criterion was not met as PM2_Supporting has been met.

BS4   Non-segregation involving this variant has not been reported.

BP4  

Although this missense variant was not predicted to affect splicing, as assessed with SpliceAI (≤ 0.1), it had a REVEL score = 0.445, which did not meet the ≤ 0.290 threshold required for BP4.

BP7	 	This criterion did not apply to this variant.
PS1	 	An established likely pathogenic or pathogenic variant causing this same amino acid change has not been identified.
PS2	 	This variant has not been identified de novo.
PS3	 	PS3_Supporting was not applied as the assays reported did not meet the OddsPath threshold (> 2.1) or the threshold for abnormal impact on protein function in the assay could not be determined (PMID: 27243976). <hr/> <p>Did not meet the OddsPath threshold for PS3_Supporting (> 2.1) or unable to determine threshold for abnormal impact on protein function in the assay. PubMed:27243976 </p>

Curation History

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.